The inorganic phosphate/inorganic pyrophosphate axis in the mineralization of cartilage and bone

Current Opinion in Orthopaedics

Volumn 18, Issue 5, 2007, Pages 454-459

  Zaka, Raihana ^a   Williams, Charlene J ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Alkaline phosphatase; Ank; Hosphodiesterase; Inorganic phosphate; Inorganic pyrophosphate; Osteopontin; Phosphomonoesterase

Indexed keywords

PHOSPHATASE; PHOSPHATE; PHOSPHODIESTERASE; PYROPHOSPHATE;

BIOLOGICAL MODEL; BONE MINERALIZATION; CARTILAGE; HOMEOSTASIS; HUMAN; HYPOPHOSPHATASIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 34547908120     PISSN: 10419918     EISSN: None     Source Type: Journal    
DOI: 10.1097/BCO.0b013e328285dffc     Document Type: Review

References (35)

1. Beck GR, Zerber B, Moran E. Phosphate is a specific signal for induction of osteopontin gene expression. Proc Natl Acad Sci U S A 2000; 97:8352-8357.
2. Beck GR, Moran E, Knecht N. Inorganic phosphate regulates multiple genes during osteoblast differentiation, including Nrf2. Exp Cell Res 2003; 288:288-300.
3. Beck GR, Knecht N. Osteopontin regulation by inorganic phosphate is ERK1/2-, protein kinase C-, and proteosome-dependent. J Biol Chem 2003; 278:41921-41929.
4. Julien M, Magne D, Masson M, et al. Phosphate stimulates matrix Gla protein expression in chondrocytes through the extracellular signal regulated kinase signaling pathway. Endocrinology 2007; 148:530-537. This report is the first demonstration that MGP expression is Pi dependent and is regulated by the ERK1/2 signaling pathway.
5. Addison WN, Azari F, Sorensen ES, et al. Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, upregulating osteopontin and inhibiting alkaline phosphatase activity. J Biol Chem 2007; 21:15872-15883. This study presents evidence that mineralization in MC3T3E1 cells occurs by at least three different mechanisms, including induction of Opn expression and inhibition of Tnap activity.
6. Rosenthal AK, Gohr CM, Uzuki M, Masuda I. Osteopontin promotes pathologic mineralization in articular cartilage. Matrix Biol 2007; 26:96-105. This study reported that the addition of OPN to articular chondrocytes in culture appears to stimulate the ATP-induced formation of CPPD crystals, which are associated with pathology in chondrocalcinosis patients.
7. Hatch NE, Nociti F, Swanson E, et al. FGF2 alters expression of the pyrophosphate/phosphate regulating proteins, PC-1, ANK, and TNAP, in the calvarial osteoblastic cell line, MC3T3E1(C4). Connect Tissue Res 2005; 46:184-192.
8. Suzuki A, Ghayor C, Guicheux J, et al. Enhanced expression of the inorganic phosphate transporter Pit-1 is involved in BMP-2-induced matrix mineralization in osteoblast-like cells. J Bone Miner Res 2006; 21:674-683.
9. Palmer G, Guicheux J, Bonjour JP, Caverzasio J. Transforming growth factor beta stimulates inorganic phosphate transport and expression of the type III phosphate transporter Glvr-1 in chondrogenic ATDC5 cells. Endocrinology 2000; 141:2236-2243.
10. i levels [abstract]. Arthritis Rheum 2004; 50:S248.
11. Cecil DL, Rose DM, Terkeltaub R, Liu-Bryan R. Role of interleukin-8 in Pit-1 expression and CXCR1-mediated inorganic phosphate uptake in chondrocytes. Arthritis Rheum 2005; 52:144-154.
12. Sakamoto M, Hosoda Y, Kojimahara K, et al. Arthritis and ankylosis in twy mice with hereditary multiple osteochondral lesions: with special reference to calcium deposition. Pathol Int 1994; 44:420-427.
13. i and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. J Bone Miner Res 2003; 18:994-1004.
14. Narisawa S, Frohlander N, Millan JL. Inactivation of two mouse alkaline phosphatase genes and establishment of a model of infantile hypophosphatasia. Dev Dyn 1997; 208:432-446.
15. Fedde KN, Blair L, Silverstein J, et al. Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia. J Bone Miner Res 1999; 14:2015-2026.
16. Hessle L, Johnson KA, Anderson HC, et al. Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci U S A 2002; 99:9445-9449.
17. Hakim FT, Cranley R, Brown KS, et al. Hereditary joint disorder in progressive ankylosis (ank/ank) mice. Arthritis Rheum 1984; 27:1411-1420.
18. Ho AM, Johnson MD, Kingsley DM. Role of the mouse ank gene in control of tissue calcification and arthritis. Science 2000; 289:265-269.
19. Harmey D, Hessle L, Narisawa S, et al. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol 2004; 164:1199-1209.
20. i on mineralization are coordinately regulated.
21. Wang W, Xu J, Du B, Kirsch T. Role of progressive ankylosis gene (ank) in cartilage mineralization. Mol Cell Biol 2005; 25:312-323.
22. Sohn P, Crowley M, Slattery E, Serra R. Developmental and TGF-beta-mediated regulation of Ank mRNA expression in cartilage and bone. Osteoarthritis Cartilage 2002; 10:482-490.
23. Pendleton A, Johnson MD, Hughes A, et al. Mutations in ANKH cause chondrocalcinosis. Am J Hum Genet 2002; 71:933-940.
24. Williams CJ, Zhang Y, Timms A, et al. Autosomal dominant familial calcium pyrophosphate dihydrate deposition disease is caused by mutation in the transmembrane protein ANKH. Am J Hum Genet 2002; 71:985-991.
25. Williams CJ, Pendleton A, Bonavita G, et al. Mutations in the amino terminus of ANKH in two US families with calcium pyrophosphate dihydrate crystal deposition disease. Arthritis Rheum 2003; 48:2627-2631.
26. Reichenberger E, Tiziani V, Watanabe S, et al. Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK. Am J Hum Genet 2001; 68:1321-1326.
27. Nurnberg P, Thiele H, Chandler D, et al. Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. Nat Genet 2001; 28:37-41.
28. i by the P5L (proline position 5 to leucine) ANK mutant, but due to the modifying effects of Tnap, only basic calcium phosphate crystals are generated in the ATDC5 system used.
29. Reginato AM, Olsen BR. Genetics and experimental models of crystalinduced arthritis. Lessons learned from mice and men: is it crystal clear? Curr Opin Rheum 2007; 19:134-145. This is an excellent review of many studies of mineralization pathologies in both humans and animal model systems.
30. Quarles LD. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab 2003; 285:E1-E9.
31. De Beur SM, Finnegan RB, Vassiliadis J, et al. Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res 2002; 17:1102-1110.
32. Feng JQ, Ward LM, Liu S, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006; 38:1310-1315.
33. Gijsbers R, Ceulemans H, Stalmans W, Bollen M. Structural and catalytic similarities between nucleotide pyrophosphatases/phosphodiesterases and alkaline phosphatases. J Biol Chem 2001; 276:1361-1368.
34. 2+ and phosphate deposition in isolated chicken matrix vesicles. J Biol Chem 2005; 280:37289-37296.
35. Garimella R, Bi X, Anderson HC, Camacho NP. Nature of phosphate substrate as a major determinant of mineral type formed in matrix vesicle-mediated in vitro mineralization: an FTIR imaging study. Bone 2006; 38:811-817.